Risk Factors for Major Adverse Cardiovascular Events in Phase <scp>III</scp> and Long‐Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis

Abstract

In this post hoc analysis, after 24 weeks of tofacitinib treatment, increased HDL cholesterol, but not increased LDL cholesterol or total cholesterol, appeared to be associated with lower future MACE risk. Further data are needed to test the cardiovascular safety of tofacitinib.